1
|
Wu B, Chen X, Cao C. Advances in Nasopharyngeal Carcinoma Staging: from the 7th to the 9th Edition of the TNM System and Future Outlook. Curr Oncol Rep 2025; 27:322-332. [PMID: 39998781 DOI: 10.1007/s11912-025-01651-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/06/2025] [Indexed: 02/27/2025]
Abstract
PURPOSE OF REVIEW Nasopharyngeal carcinoma (NPC), characterized by its aggressive nature and sensitivity to radiation, demands accurate staging for optimal clinical outcomes. The purpose of this review was to provides a comprehensive overview of the evolution of the TNM staging system for NPC based on recent and previously published studies, with particular emphasis on the transition from the 7th to the 9th edition. RECENT FINDINGS The 9th edition introduces critical changes, particularly in the N and M classifications, to enhance prognostic accuracy. Our analysis also incorporates the burgeoning roles of biomarkers, especially Epstein-Barr virus (EBV)-DNA, and the potential of Artificial Intelligence (AI) in refining NPC staging. Each iteration of the TNM staging system for NPC has successfully enhanced the prognostic precision of NPC, with notable advancements from the 7th to the 9th edition. We also delves into the incorporation of biomarkers, such as EBV-DNA, and the potential of AI in refining staging accuracy. These innovations are anticipated to offer personalized prognoses and inform tailored treatment strategies for NPC patients in the future.
Collapse
Affiliation(s)
- Binhao Wu
- Department of Radiation Oncology, Chinese Academy of Sciences; Key Laboratory of Head & Neck Cancer Translational Research of Zhejiang Province, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Zhejiang, China
- Postgraduate training base Alliance of Wenzhou Medical University (Zhejiang Cancer Hospital), Hangzhou, 310022, Zhejiang, China
| | - Xiaozhong Chen
- Department of Radiation Oncology, Chinese Academy of Sciences; Key Laboratory of Head & Neck Cancer Translational Research of Zhejiang Province, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Zhejiang, China
| | - Caineng Cao
- Department of Radiation Oncology, Chinese Academy of Sciences; Key Laboratory of Head & Neck Cancer Translational Research of Zhejiang Province, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), Zhejiang, China.
- Department of Radiation Oncology, Chinese Academy of Sciences; Key Laboratory of Head & Neck Cancer Translational Research of Zhejiang Province, The Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital), Institute of Basic Medicine and Cancer (IBMC), No 1, East Banshan Road, Gongshu District, Hangzhou, 310022, China.
| |
Collapse
|
2
|
Wu X, Wang J, Chen C, Cai W, Guo Y, Guo K, Chen Y, Shi Y, Chen J, Lin X, Jiang X. Integration of Deep Learning and Sub-regional Radiomics Improves the Prediction of Pathological Complete Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer Patients. Acad Radiol 2025:S1076-6332(24)01037-7. [PMID: 39809603 DOI: 10.1016/j.acra.2024.12.049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2024] [Revised: 12/20/2024] [Accepted: 12/21/2024] [Indexed: 01/16/2025]
Abstract
RATIONALE AND OBJECTIVES The precise prediction of response to neoadjuvant chemoradiotherapy is crucial for tailoring perioperative treatment in patients diagnosed with locally advanced rectal cancer (LARC). This retrospective study aims to develop and validate a model that integrates deep learning and sub-regional radiomics from MRI imaging to predict pathological complete response (pCR) in patients with LARC. MATERIALS AND METHODS We retrospectively enrolled 768 eligible participants from three independent hospitals who had received neoadjuvant chemoradiotherapy followed by radical surgery. Pretreatment pelvic MRI scans (T2-weighted), were collected for annotation and feature extraction. The K-means approach was used to segment the tumor into sub-regions. Radiomics and deep learning features were extracted by the Pyradiomics and 3D ResNet50, respectively. The predictive models were developed using the radiomics, sub-regional radiomics, and deep learning features with the machine learning algorithm in training cohort, and then validated in the external tests. The models' performance was assessed using various metrics, including the area under the curve (AUC), decision curve analysis, Kaplan-Meier survival analysis. RESULTS We constructed a combined model, named SRADL, which includes deep learning with sub-regional radiomics signatures, enabling precise prediction of pCR in LARC patients. SRADL had satisfactory performance for the prediction of pCR in the training cohort (AUC 0.925 [95% CI 0.894 to 0.948]), and in test 1 (AUC 0.915 [95% CI 0.869 to 0.949]) and in test 2 (AUC 0.902 [95% CI 0.846 to 0.945]). By employing optimal threshold of 0.486, the predicted pCR group had longer survival compared to predicted non-pCR group across three cohorts. SRADL also outperformed other single-modality prediction models. CONCLUSION The novel SRADL, which integrates deep learning with sub-regional signatures, showed high accuracy and robustness in predicting pCR to neoadjuvant chemoradiotherapy using pretreatment MRI images, making it a promising tool for the personalized management of LARC.
Collapse
Affiliation(s)
- Xixi Wu
- Department of Gastroenterology and Hepatology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China (X.W., C.C., W.C., Y.G., X.L., X.J.); Department of Pathology, Wenzhou Hospital of Integrated Traditional Chinese and Western Medicine Hospital, Wenzhou 325000, China (X.W., J.W., C.C., W.C., Y.G., K.G., Y.C., Y.S., J.C., X.L., X.J.).
| | - Jinyong Wang
- Department of Infectious, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China (J.W., K.G.); Department of Pathology, Wenzhou Hospital of Integrated Traditional Chinese and Western Medicine Hospital, Wenzhou 325000, China (X.W., J.W., C.C., W.C., Y.G., K.G., Y.C., Y.S., J.C., X.L., X.J.).
| | - Chao Chen
- Department of Gastroenterology and Hepatology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China (X.W., C.C., W.C., Y.G., X.L., X.J.); Department of Pathology, Wenzhou Hospital of Integrated Traditional Chinese and Western Medicine Hospital, Wenzhou 325000, China (X.W., J.W., C.C., W.C., Y.G., K.G., Y.C., Y.S., J.C., X.L., X.J.).
| | - Weimin Cai
- Department of Gastroenterology and Hepatology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China (X.W., C.C., W.C., Y.G., X.L., X.J.); Department of Pathology, Wenzhou Hospital of Integrated Traditional Chinese and Western Medicine Hospital, Wenzhou 325000, China (X.W., J.W., C.C., W.C., Y.G., K.G., Y.C., Y.S., J.C., X.L., X.J.).
| | - Yu Guo
- Department of Gastroenterology and Hepatology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China (X.W., C.C., W.C., Y.G., X.L., X.J.); Department of Pathology, Wenzhou Hospital of Integrated Traditional Chinese and Western Medicine Hospital, Wenzhou 325000, China (X.W., J.W., C.C., W.C., Y.G., K.G., Y.C., Y.S., J.C., X.L., X.J.).
| | - Kun Guo
- Department of Infectious, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China (J.W., K.G.); Department of Pathology, Wenzhou Hospital of Integrated Traditional Chinese and Western Medicine Hospital, Wenzhou 325000, China (X.W., J.W., C.C., W.C., Y.G., K.G., Y.C., Y.S., J.C., X.L., X.J.).
| | - Yongxian Chen
- Department of Pathology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China (Y.C.); Department of Pathology, Wenzhou Hospital of Integrated Traditional Chinese and Western Medicine Hospital, Wenzhou 325000, China (X.W., J.W., C.C., W.C., Y.G., K.G., Y.C., Y.S., J.C., X.L., X.J.).
| | - Yubo Shi
- Department of Pathology, Xiamen Medical College Affiliated Second Hospital, Xiamen 36100, China (Y.S.); Department of Pathology, Wenzhou Hospital of Integrated Traditional Chinese and Western Medicine Hospital, Wenzhou 325000, China (X.W., J.W., C.C., W.C., Y.G., K.G., Y.C., Y.S., J.C., X.L., X.J.).
| | - Junkai Chen
- Department of Radiology, Yueqing People's Hospital, Wenzhou 325000, China (J.C.); Department of Pathology, Wenzhou Hospital of Integrated Traditional Chinese and Western Medicine Hospital, Wenzhou 325000, China (X.W., J.W., C.C., W.C., Y.G., K.G., Y.C., Y.S., J.C., X.L., X.J.).
| | - Xinran Lin
- Department of Gastroenterology and Hepatology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China (X.W., C.C., W.C., Y.G., X.L., X.J.); Department of Pathology, Wenzhou Hospital of Integrated Traditional Chinese and Western Medicine Hospital, Wenzhou 325000, China (X.W., J.W., C.C., W.C., Y.G., K.G., Y.C., Y.S., J.C., X.L., X.J.)
| | - Xuepei Jiang
- Department of Gastroenterology and Hepatology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou 325000, China (X.W., C.C., W.C., Y.G., X.L., X.J.); Department of Pathology, Wenzhou Hospital of Integrated Traditional Chinese and Western Medicine Hospital, Wenzhou 325000, China (X.W., J.W., C.C., W.C., Y.G., K.G., Y.C., Y.S., J.C., X.L., X.J.).
| |
Collapse
|
3
|
Zhang X, Zheng W, Huang S, Li H, Bi Z, Yang X. Xerostomia prediction in patients with nasopharyngeal carcinoma during radiotherapy using segmental dose distribution in dosiomics and radiomics models. Oral Oncol 2024; 158:107000. [PMID: 39226775 DOI: 10.1016/j.oraloncology.2024.107000] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2024] [Revised: 07/31/2024] [Accepted: 08/14/2024] [Indexed: 09/05/2024]
Abstract
OBJECTIVES This study aimed to integrate radiomics and dosiomics features to develop a predictive model for xerostomia (XM) in nasopharyngeal carcinoma after radiotherapy. It explores the influence of distinct feature extraction methods and dose ranges on the performance. MATERIALS AND METHODS Data from 363 patients with nasopharyngeal carcinoma were retrospectively analyzed. We pioneered a dose-segmentation strategy, where the overall dose distribution (OD) was divided into four segmental dose distributions (SDs) at intervals of 15 Gy. Features were extracted using manual definition and deep learning, applying OD or SD and integrating radiomics and dosiomics, yielding corresponding feature scores (manually defined radiomics, MDR; manually defined dosiomics, MDD; deep learning-based radiomics, DLR; deep learning-based dosiomics, DLD). Subsequently, 18 models were developed by combining features and model types (random forest and support vector machine). RESULTS AND CONCLUSION Under OD, O(DLR_DLD) demonstrated exceptional performance, with an optimal area under the curve (AUC) of 0.81 and an average AUC of 0.71. Within SD, S(DLR_DLD) surpassed the other models, achieving an optimal AUC of 0.90 and an average AUC of 0.85. Therefore, the integration of dosiomics into radiomics can augment predictive efficacy. The dose-segmentation strategy can facilitate the extraction of more profound information. This indicates that ScoreDLR and ScoreMDR were negatively associated with XM, whereas ScoreDLD, derived from SD exceeding 15 Gy, displayed a positive association with XM. For feature extraction, deep learning was superior to manual definition.
Collapse
Affiliation(s)
- Xushi Zhang
- State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou 510060, Guangdong Province, China; School of Biomedical Engineering, Guangzhou Medical University, Guangzhou 511400, Guangdong Province, China.
| | - Wanjia Zheng
- Department of Radiation Oncology, Southern Theater Air Force Hospital of the People's Liberation Army, Guangzhou 510050, Guangdong Province, China.
| | - Sijuan Huang
- State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou 510060, Guangdong Province, China.
| | - Haojiang Li
- State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou 510060, Guangdong Province, China.
| | - Zhisheng Bi
- School of Biomedical Engineering, Guangzhou Medical University, Guangzhou 511400, Guangdong Province, China; Department of Emergency Medicine, the Second Affiliated Hospital, Guangzhou Medical University, Guangzhou 510260, Guangdong Province, China.
| | - Xin Yang
- State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou 510060, Guangdong Province, China.
| |
Collapse
|
4
|
Chamseddine I, Shah K, Lee H, Ehret F, Schuemann J, Bertolet A, Shih HA, Paganetti H. Decoding Patient Heterogeneity Influencing Radiation-Induced Brain Necrosis. Clin Cancer Res 2024; 30:4424-4433. [PMID: 39106090 PMCID: PMC11444871 DOI: 10.1158/1078-0432.ccr-24-1215] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2024] [Revised: 06/27/2024] [Accepted: 08/02/2024] [Indexed: 08/07/2024]
Abstract
PURPOSE In radiotherapy (RT) for brain tumors, patient heterogeneity masks treatment effects, complicating the prediction and mitigation of radiation-induced brain necrosis. Therefore, understanding this heterogeneity is essential for improving outcome assessments and reducing toxicity. EXPERIMENTAL DESIGN We developed a clinically practical pipeline to clarify the relationship between dosimetric features and outcomes by identifying key variables. We processed data from a cohort of 130 patients treated with proton therapy for brain and head and neck tumors, utilizing an expert-augmented Bayesian network to understand variable interdependencies and assess structural dependencies. Critical evaluation involved a three-level grading system for each network connection and a Markov blanket analysis to identify variables directly impacting necrosis risk. Statistical assessments included log-likelihood ratio, integrated discrimination index, net reclassification index, and receiver operating characteristic (ROC). RESULTS The analysis highlighted tumor location and proximity to critical structures such as white matter and ventricles as major determinants of necrosis risk. The majority of network connections were clinically supported, with quantitative measures confirming the significance of these variables in patient stratification (log-likelihood ratio = 12.17; P = 0.016; integrated discrimination index = 0.15; net reclassification index = 0.74). The ROC curve area was 0.66, emphasizing the discriminative value of nondosimetric variables. CONCLUSIONS Key patient variables critical to understanding brain necrosis post-RT were identified, aiding the study of dosimetric impacts and providing treatment confounders and moderators. This pipeline aims to enhance outcome assessments by revealing at-risk patients, offering a versatile tool for broader applications in RT to improve treatment personalization in different disease sites.
Collapse
Affiliation(s)
- Ibrahim Chamseddine
- Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, USA
| | - Keyur Shah
- Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, USA
| | - Hoyeon Lee
- Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, USA
| | - Felix Ehret
- Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, USA
- Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Department of Radiation Oncology, Berlin, Germany
- German Cancer Consortium (DKTK), partner site Berlin, a partnership between DKFZ and Charité – Universitätsmedizin Berlin, Germany
| | - Jan Schuemann
- Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, USA
| | - Alejandro Bertolet
- Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, USA
| | - Helen A. Shih
- Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, USA
| | - Harald Paganetti
- Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, USA
| |
Collapse
|
5
|
Wang L, Qiu T, Zhou J, Zhu Y, Sun B, Yang G, Huang S, Wu L, He X. A pretreatment multiparametric MRI-based radiomics-clinical machine learning model for predicting radiation-induced temporal lobe injury in patients with nasopharyngeal carcinoma. Head Neck 2024; 46:2132-2144. [PMID: 38887926 DOI: 10.1002/hed.27830] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/19/2024] [Revised: 05/11/2024] [Accepted: 05/22/2024] [Indexed: 06/20/2024] Open
Abstract
BACKGROUND To establish and validate a machine learning model using pretreatment multiparametric magnetic resonance imaging-based radiomics data with clinical data to predict radiation-induced temporal lobe injury (RTLI) in patients with nasopharyngeal carcinoma (NPC) after intensity-modulated radiotherapy (IMRT). METHODS Data from 230 patients with NPC who received IMRT (130 with RTLI and 130 without) were randomly divided into the training (n = 161) and validation cohort (n = 69) with a ratio of 7:3. Radiomics features were extracted from pretreatment apparent diffusion coefficient (ADC) map, T2-weighted imaging (T2WI), and CE-T1-weighted imaging (CE-T1WI). T-test, spearman rank correlation, and least absolute shrinkage and selection operator (LASSO) algorithm were employed to identify significant radiomics features. Clinical features were selected with univariate and multivariate analyses. Radiomics and clinical models were constructed using multiple machine learning classifiers, and a clinical-radiomics nomogram that combined clinical with radiomics features was developed. Receiver operating characteristic (ROC) curves, calibration curves, and decision curve analysis (DCA) were drawn to compare and verify the predictive performances of the clinical model, radiomics model, and clinical-radiomics nomogram. RESULTS A total of 5064 radiomics features were extracted, from which 52 radiomics features were selected to construct the radiomics signature. The AUC of the radiomics signature based on multiparametric MRI was 0.980 in the training cohort and 0.969 in the validation cohort, outperforming the radiomics signature only based on T2WI and CE-T1WI (p < 0.05), which highlighted the significance of the DWI sequence in the prediction of temporal lobe injury. The area under the curve (AUC) of the clinical model was 0.895 in the training cohort and 0.905 in the validation cohort. The nomogram, which integrated radiomics and clinical features, demonstrated an impressive AUC value of 0.984 in the validation set; however, no statistically significant difference was observed compared to the radiomics model. The calibration curve and decision curve analysis of the nomogram demonstrated excellent predictive performance and clinical feasibility. CONCLUSIONS The clinical-radiomics nomogram, integrating clinical features with radiomics features derived from pretreatment multiparametric MRI, exhibits compelling predictive performance for RTLI in patients diagnosed with NPC.
Collapse
Affiliation(s)
- Li Wang
- Department of Radiation Oncology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China
| | - Ting Qiu
- Department of Radiation Oncology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China
| | - Jiawei Zhou
- Department of Radiation Oncology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China
| | - Yinsu Zhu
- Department of Radiology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China
| | - Baozhou Sun
- Department of Radiation Oncology, Baylor College of Medicine, Houston, Texas, USA
| | - Guanyu Yang
- Key Laboratory of Computer Network and Information Integration, Southeast University, Nanjing, China
| | - Shengfu Huang
- Department of Radiation Oncology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China
| | - Lirong Wu
- Department of Radiation Oncology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China
| | - Xia He
- Department of Radiation Oncology, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing, China
| |
Collapse
|
6
|
Lucas JT, Abramson ZR, Epstein K, Morin CE, Jaju A, Lee JW, Lee CL, Sitaram R, Voss SD, Hudson MM, Constine LS, Hua CH. Imaging Assessment of Radiation Therapy-Related Normal Tissue Injury in Children: A PENTEC Visionary Statement. Int J Radiat Oncol Biol Phys 2024; 119:669-680. [PMID: 38760116 PMCID: PMC11684541 DOI: 10.1016/j.ijrobp.2024.03.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2024] [Accepted: 03/08/2024] [Indexed: 05/19/2024]
Abstract
The Pediatric Normal Tissue Effects in the Clinic (PENTEC) consortium has made significant contributions to understanding and mitigating the adverse effects of childhood cancer therapy. This review addresses the role of diagnostic imaging in detecting, screening, and comprehending radiation therapy-related late effects in children, drawing insights from individual organ-specific PENTEC reports. We further explore how the development of imaging biomarkers for key organ systems, alongside technical advancements and translational imaging approaches, may enhance the systematic application of imaging evaluations in childhood cancer survivors. Moreover, the review critically examines knowledge gaps and identifies technical and practical limitations of existing imaging modalities in the pediatric population. Addressing these challenges may expand access to, minimize the risk of, and optimize the real-world application of, new imaging techniques. The PENTEC team envisions this document as a roadmap for the future development of imaging strategies in childhood cancer survivors, with the overarching goal of improving long-term health outcomes and quality of life for this vulnerable population.
Collapse
Affiliation(s)
| | - Zachary R Abramson
- Diagnostic Imaging, St. Jude Children's Research Hospital, Memphis, Tennessee
| | - Katherine Epstein
- Division of Radiology and Medical Imaging, UC Department of Radiology, Cincinnati, Ohio
| | - Cara E Morin
- Division of Radiology and Medical Imaging, UC Department of Radiology, Cincinnati, Ohio
| | - Alok Jaju
- Department of Medical Imaging, Ann and Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, Illinois
| | | | - Chang-Lung Lee
- Department of Radiation Oncology and; Pathology, Duke University School of Medicine, Durham, North Carolina
| | - Ranganatha Sitaram
- Diagnostic Imaging, St. Jude Children's Research Hospital, Memphis, Tennessee
| | - Stephan D Voss
- Department of Radiology, Harvard Medical School, Boston, Massachusetts
| | - Melissa M Hudson
- Department of Oncology, St. Jude Children's Research Hospital, Memphis, Tennessee
| | - Louis S Constine
- Department of Radiation Oncology, James P. Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, New York
| | | |
Collapse
|
7
|
Dong J, Ng WT, Wong CHL, Li JS, Bollen H, Chow JCH, Eisbruch A, Lee AWM, Lee VHF, Ng SP, Nuyts S, Smee R, Ferlito A. Dosimetric parameters predict radiation-induced temporal lobe necrosis in nasopharyngeal carcinoma patients: A systematic review and meta-analysis. Radiother Oncol 2024; 195:110258. [PMID: 38537680 DOI: 10.1016/j.radonc.2024.110258] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2023] [Revised: 03/18/2024] [Accepted: 03/21/2024] [Indexed: 04/07/2024]
Abstract
This systematic review examines the role of dosimetric parameters in predicting temporal lobe necrosis (TLN) risk in nasopharyngeal carcinoma (NPC) patients treated with three-dimensional conformal RT (3D-CRT), intensity-modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT). TLN is a serious late complication that can adversely affect the quality of life of NPC patients. Understanding the relationship between dosimetric parameters and TLN can guide treatment planning and minimize radiation-related complications. A comprehensive search identified relevant studies published up to July 2023. Studies reporting on dosimetric parameters and TLN in NPC patients undergoing 3D-CRT, IMRT, and VMAT were included. TLN incidence, follow-up duration, and correlation with dosimetric parameters of the temporal lobe were analyzed. The review included 30 studies with median follow-up durations ranging from 28 to 110 months. The crude incidence of TLN varied from 2.3 % to 47.3 % and the average crude incidence of TLN is approximately 14 %. Dmax and D1cc emerged as potential predictors of TLN in 3D-CRT and IMRT-treated NPC patients. Threshold values of >72 Gy for Dmax and >62 Gy for D1cc were associated with increased TLN risk. However, other factors should also be considered, including host characteristics, tumor-specific features and therapeutic factors. In conclusion, this systematic review highlights the significance of dosimetric parameters, particularly Dmax and D1cc, in predicting TLN risk in NPC patients undergoing 3D-CRT, IMRT, and VMAT. The findings provide valuable insights that can help in developing optimal treatment planning strategies and contribute to the development of clinical guidelines in this field.
Collapse
Affiliation(s)
- Jun Dong
- Clinical Oncology Center, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China
| | - Wai Tong Ng
- Clinical Oncology Center, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China; Department of Clinical Oncology, Shenzhen Key Laboratory for Cancer Metastasis and Personalized Therapy, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China; Department of Clinical Oncology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China.
| | - Charlene H L Wong
- Department of Clinical Oncology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China
| | - Ji-Shi Li
- Clinical Oncology Center, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China
| | - Heleen Bollen
- Laboratory of Experimental Radiotherapy, Department of Oncology, KU Leuven, Belgium; Department of Radiation Oncology, Leuven Cancer Institute, University Hospitals Leuven, Belgium
| | - James C H Chow
- Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong SAR, China
| | - Avraham Eisbruch
- Department of Radiation Oncology, University of Michigan Medicine, Ann Arbor, MI, USA
| | - Anne W M Lee
- Clinical Oncology Center, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China; Department of Clinical Oncology, Shenzhen Key Laboratory for Cancer Metastasis and Personalized Therapy, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China; Department of Clinical Oncology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China
| | - Victor H F Lee
- Department of Clinical Oncology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China
| | - Sweet Ping Ng
- Department of Radiation Oncology, Olivia Newton-John Cancer and Wellness Centre, Austin Health, Melbourne, Australia
| | - Sandra Nuyts
- Laboratory of Experimental Radiotherapy, Department of Oncology, KU Leuven, Belgium; Department of Radiation Oncology, Leuven Cancer Institute, University Hospitals Leuven, Belgium
| | - Robert Smee
- Department of Radiation Oncology, The Prince of Wales Cancer Centre, Sydney, Australia
| | - Alfio Ferlito
- Coordinator of the International Head and Neck Scientific Group, Padua, Italy
| |
Collapse
|
8
|
Wang CK, Wang TW, Lu CF, Wu YT, Hua MW. Deciphering the Prognostic Efficacy of MRI Radiomics in Nasopharyngeal Carcinoma: A Comprehensive Meta-Analysis. Diagnostics (Basel) 2024; 14:924. [PMID: 38732337 PMCID: PMC11082984 DOI: 10.3390/diagnostics14090924] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2024] [Revised: 04/12/2024] [Accepted: 04/24/2024] [Indexed: 05/13/2024] Open
Abstract
This meta-analysis investigates the prognostic value of MRI-based radiomics in nasopharyngeal carcinoma treatment outcomes, specifically focusing on overall survival (OS) variability. The study protocol was registered with INPLASY (INPLASY202420101). Initially, a systematic review identified 15 relevant studies involving 6243 patients through a comprehensive search across PubMed, Embase, and Web of Science, adhering to PRISMA guidelines. The methodological quality was assessed using the Quality in Prognosis Studies (QUIPS) tool and the Radiomics Quality Score (RQS), highlighting a low risk of bias in most domains. Our analysis revealed a significant average concordance index (c-index) of 72% across studies, indicating the potential of radiomics in clinical prognostication. However, moderate heterogeneity was observed, particularly in OS predictions. Subgroup analyses and meta-regression identified validation methods and radiomics software as significant heterogeneity moderators. Notably, the number of features in the prognosis model correlated positively with its performance. These findings suggest radiomics' promising role in enhancing cancer treatment strategies, though the observed heterogeneity and potential biases call for cautious interpretation and standardization in future research.
Collapse
Affiliation(s)
- Chih-Keng Wang
- School of Medicine, College of Medicine, National Yang-Ming Chiao Tung University, Taipei 112304, Taiwan
- Department of Otolaryngology-Head and Neck Surgery, Taichung Veterans General Hospital, Taichung 407219, Taiwan
| | - Ting-Wei Wang
- School of Medicine, College of Medicine, National Yang-Ming Chiao Tung University, Taipei 112304, Taiwan
- Institute of Biophotonics, National Yang-Ming Chiao Tung University, 155, Sec. 2, Li-Nong St. Beitou Dist., Taipei 112304, Taiwan
| | - Chia-Fung Lu
- Department of Biomedical Imaging and Radiological Sciences, National Yang-Ming Chiao Tung University, Taipei 112304, Taiwan;
| | - Yu-Te Wu
- Institute of Biophotonics, National Yang-Ming Chiao Tung University, 155, Sec. 2, Li-Nong St. Beitou Dist., Taipei 112304, Taiwan
| | - Man-Wei Hua
- Department of Otolaryngology-Head and Neck Surgery, Taichung Veterans General Hospital, Taichung 407219, Taiwan
| |
Collapse
|